Home › Free Stock Grades › BDTX
Black Diamond Therapeutics, Inc. (BDTX) Stock Grade
BDTX · Healthcare
A+
Market Cap
$138.2M
P/E Ratio
6.2
Revenue Growth (YoY)
0.0%
Net Margin
32.0%
Return on Equity
19.9%
Dividend Yield
None
About Black Diamond Therapeutics, Inc.'s fundamentals
Black Diamond Therapeutics is a small-cap biotechnology company with a market capitalization of $138.2M that currently generates no year-over-year revenue growth. Despite flat revenue, the company maintains a notably strong net profit margin of 32.0% and achieves a return on equity of 19.9%, indicating efficient profitability from its existing operations. The stock trades at a low P/E ratio of 6.2 and does not offer dividend income, typical characteristics of early-stage or unprofitable biotech firms, though the positive margins suggest the company is currently profitable.